Sorafenib is contraindicated in patients with known severe hypersensitivity to sorafenib or any other component of Sorafenib.
Sorafenib in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer.
Other Services
Country
Account